<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pediatr Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">J Pediatr Pharmacol Ther</journal-id><journal-id journal-id-type="pmc-domain-id">1334</journal-id><journal-id journal-id-type="pmc-domain">jppt</journal-id><journal-id journal-id-type="publisher-id">jppt</journal-id><journal-title-group><journal-title>The Journal of Pediatric Pharmacology and Therapeutics : JPPT</journal-title></journal-title-group><issn pub-type="ppub">1551-6776</issn><issn pub-type="epub">2331-348X</issn><publisher><publisher-name>Pediatric Pharmacology Advocacy Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5040175</article-id><article-id pub-id-type="pmcid-ver">PMC5040175.1</article-id><article-id pub-id-type="pmcaid">5040175</article-id><article-id pub-id-type="pmcaiid">5040175</article-id><article-id pub-id-type="pmid">27713671</article-id><article-id pub-id-type="doi">10.5863/1551-6776-21.4.322</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical Investigations</subject></subj-group></article-categories><title-group><article-title>Stability and Sterility of Enoxaparin 8 mg/mL Subcutaneous Injectable Solution</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Moffett</surname><given-names initials="BS">Brady S.</given-names></name><degrees>PharmD, MPH</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dinh</surname><given-names initials="K">Kimberly</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Placencia</surname><given-names initials="J">Jennifer</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pelkey</surname><given-names initials="G">Gregory</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hui</surname><given-names initials="SKR">Shiu-Ki Rocky</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Teruya</surname><given-names initials="J">Jun</given-names></name><degrees>MD, DSc</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><aff id="aff1"><label>1</label>Department of Pharmacy, Texas Children's Hospital, Houston, Texas
</aff><aff id="aff2"><label>2</label>Department of Laboratory, Texas Children's Hospital, Houston, Texas
</aff><aff id="aff3"><label>3</label>Department of Pathology &amp; Immunology, Pediatrics, Baylor College of Medicine, Houston, Texas
</aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold> Brady S. Mofiett, PharmD, MPH, Texas Children's Hospital, Department of Pharmacy, 6621 Fannin Street, Suite WB1120, Houston, TX 77030, email: <email>bsmofiet@texaschildrens.org</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2016</year></pub-date><volume>21</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">276223</issue-id><fpage>322</fpage><lpage>326</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2016</year></date></event><event event-type="pmc-live"><date><day>06</day><month>10</month><year>2016</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-07-25 19:25:09.313"><day>25</day><month>07</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2016 Pediatric Pharmacy Advocacy Group</copyright-statement><copyright-year>2016</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="i1551-6776-21-4-322.pdf"/><abstract><p><bold>BACKGROUND:</bold> Enoxaparin is often diluted to accurately deliver doses to neonatal and infant patients. Current recommendations for dilutions may not be adequate for the smallest patients.</p><p><bold>METHODS:</bold> Review of dosing at our institution occurred, and an 8 mg/mL concentration of enoxaparin was chosen. A concentration of 8 mg/mL was compounded by diluting 0.4 mL of enoxaparin (100 mg/mL) into 4.6 mL of sterile water for injection into an empty sterile vial. Four syringes of the 8 mg/mL concentration were prepared by 5 technicians (20 total syringes). Stability and sterility testing occurred a 0, 7, 14, and 30 days. One-way repeated-measures analysis of variance was used to detect significant differences in Anti&#8211;Factor Xa concentrations at the testing time points.</p><p><bold>RESULTS:</bold> The dilution of enoxaparin was sterile at 30 days but exhibited significant degradation at the 30-day point (p &lt; 0.05).</p><p><bold>CONCLUSION:</bold> A dilution of enoxaparin 8 mg/mL is stable and sterile for 14 days refrigerated but is not stable at 30 days.</p></abstract><kwd-group><title>INDEX TERMS:</title><kwd>Anti&#8211;Factor Xa concentrations</kwd><kwd>enoxaparin</kwd><kwd>low molecular weight heparin</kwd><kwd>neonates</kwd><kwd>stability</kwd><kwd>sterility</kwd></kwd-group><counts><page-count count="5"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>